NOT medical advice. Always consult a healthcare professional. NOT affiliated with or endorsed by the NHS, NHSBSA, MHRA, or any government body.

NOT medical advice. Always consult a qualified healthcare professional. NOT affiliated with, or endorsed by the NHS, NHSBSA, MHRA, or any government body.

NOT medical advice. Always consult a qualified healthcare professional. NOT affiliated with, or endorsed by the NHS, NHSBSA, MHRA, or any government body.

Emergency?Call 999

Need NHS advice?Call 111

Loading...

Plerixafor 24mg/1.2ml solution for injection vials

Prescription only

Requires a prescription from a doctor or prescriber

Injection

24mg/1.2ml

Parenteral

Active ingredients:

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC L03AX16

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Plerixafor

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Plerixafor

Source: MHRA Products DatabaseOGL 3.0

Updated 16 Jan 2026

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Plerixafor

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Plerixafor

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

6 branded products available

6 products

6 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Plerixafor on the MHRA register

Plerixafor 24mg/1.2ml solution for injection vials

Seacross Pharmaceuticals Ltd

Plerixafor 24mg/1.2ml solution for injection vials

Plerixafor 24mg/1.2ml solution for injection vials

Tillomed Laboratories Ltd

Plerixafor 24mg/1.2ml solution for injection vials

Accord-UK Ltd

Plerixafor 24mg/1.2ml solution for injection vials

Amarox Ltd

Mozobil 24mg/1.2ml solution for injection vials

Discontinued

Source: NHS dm+dOGL 3.0

Updated 1 Mar 2026

Daily dose

WHO defined daily dose (DDD)

16.8 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similar

Leniolisib 70mg tablets

Same therapeutic group

Methoxsalen 100micrograms/5ml solution for blood fraction modification ampoules

Same therapeutic group

RIVM strain Bacillus of Calmette-Guerin 200million-1,500million colony forming units powder and solvent for intravesical suspension vials

Same therapeutic group

Pegademase 375units/1.5ml solution for injection vials

Same therapeutic group

Bacillus Calmette-Guerin vaccine powder for suspension for injection 1ml vials

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

Pharmacy2U

Search products

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

16197611000001100

dm+d ID

16197611000001100

VTM (Virtual Therapeutic Moiety)

777232007

VMP (Virtual Medicinal Product)

16197611000001100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

L03AX16

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 18 · Randomised trials: 6 · 2008–2026

Sort

Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

John F. DiPersio, Ivana N. Micallef, Patrick J. Stiff, et al.

Journal of Clinical Oncology, 2009

Randomised trial

Cited by 610

G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis

Yuyao Li, Xia Qiu, Yupeng Lei, et al.

Annals of Medicine, 2024

Systematic review

Cited by 11

Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies.

H. Maganti, A. Visram, R. Shorr, et al.

Leukemia research, 2020

Systematic review

Cited by 24

Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis

Xiao-Yang Yang, Meng-Jie Wan, Feng Yu, et al.

Experimental and Therapeutic Medicine, 2019

Systematic review

Cited by 23

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration

E. De Clercq

Antiviral Chemistry & Chemotherapy, 2019

Review

Cited by 145

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome

D. McDermott, Daniel S. Velez, Elena Cho, et al.

The Journal of Clinical Investigation, 2023

Randomised trial

Cited by 36

Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review

Miriam Allein Zago Marcolino (6698288), Roselene Mesquita Augusto Passos (14173492), Alessandro Gonçalves Campolina (4649149), et al.

2022

Systematic review

CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent.

Jingzhe Wang, B. Tannous, M. Poznansky, et al.

Pharmacological research, 2020

Review

Cited by 114

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee, et al.

Blood, 2009

Cited by 701

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

S Giralt, E A Stadtmauer, J L Harousseau, et al.

Leukemia, 2009

Cited by 209

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

0.3 hours

Mechanism

Plerixafor inhibits the C-X-C chemokine receptor type 4 (CXCR4) on CD34+ cells a…

Food interactions

None known

Human targets

1 target

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

0.04 mg/k

Plerixafor follows a two-compartment pharmacokinetic profile with first-order absorption and exhibits linear kinetics between 0.04…

Half-life

0.3 hours

Plerixafor has a distribution half-life of 0.3 hours and a terminal population half-life of 5.3…

Protein binding

58%

The human plasma protein binding of plerixafor is up to 58%.
[L45678]

Volume of distribution

0.3 L/kg

Plerixafor has an apparent volume of distribution of 0.3 L/kg.
[L45678]

Metabolism

Plerixafor is not metabolized by the liver and is not a metabolism-dependent inhibitor of major cytochrome P450 enzymes, including 1A2, 2C9, 2C19, 2D6 and 3A4.…

Elimination

0.24 mg/k

Plerixafor is mainly eliminated through urine. In healthy volunteers with normal renal function given 0.24…

Clearance

4.38 L/h

Plerixafor has a total plasma clearance of 4.38 L/h, and a renal clearance of 3.15 L/h.
[A7116][A258423]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer.[A7117][L45678] It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells destroyed by chemotherapy.[A7118][L45678]

As an inhibitor of CXCR4, plerixafor blocks the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1α). Since CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment, blocking this interaction leads to an increase in CD34+ cell circulating levels.[A7117] Compared to placebo with G-CSF, the plerixafor and G-CSF mobilization regimen has a higher probability of achieving the optimal CD34+ cell target for tandem transplantation in fewer apheresis procedures.[A7115]

Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117][L45678]

Properties:

solid

Avg. mass: 502.78 Da

DrugBank indication

Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
[L45678]

Also known as(17)

1,1'-(1,4-phenylenebis(methylene))bis-1,4,8,11-tetraazacyclotetradecane

1,4,8,11-tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-

Plerixafor

CXC-R4

CXCR-4

FB22

Fusin

HM89

Molecular properties(18)

Drug interactions(732)

Known interactions with other medicines. Always consult a healthcare professional.

Moderate

Cyclosporine may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Icosapent may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cefotiam may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Mesalazine may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cefmenoxime may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cefmetazole may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Pamidronic acid

Moderate

Pamidronic acid may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Tenofovir disoproxil

Moderate

Tenofovir disoproxil may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Indomethacin may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cidofovir may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cefpiramide may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Ceftazidime may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Loracarbef may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cefalotin may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Nabumetone may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Ketorolac may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Tenoxicam may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Celecoxib may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cefotaxime may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Tolmetin may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Foscarnet may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Rofecoxib may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Piroxicam may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Methotrexate may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cephalexin may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Fenoprofen may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Valaciclovir may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Valdecoxib may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Diclofenac may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Sulindac may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Bacitracin may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Amphotericin B may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cephaloglycin may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Flurbiprofen may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Adefovir dipivoxil

Moderate

Adefovir dipivoxil may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Pentamidine may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Etodolac may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Mefenamic acid may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Acyclovir may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Naproxen may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Sulfasalazine may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Phenylbutazone may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Meloxicam may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Carprofen may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Cefaclor may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Diflunisal may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Tacrolimus may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Ceforanide may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Moderate

Salicylic acid may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Meclofenamic acid

Moderate

Meclofenamic acid may decrease the excretion rate of Plerixafor which could result in a higher serum level.

Check this interaction

Showing 50 of 732 interactions

Toxicity & overdose

There is limited data about the effects of plerixafor at doses higher than the recommended (0.24 mg/kg subcutaneously). However, the frequency of gastrointestinal disorders, vasovagal reactions, orthostatic hypotension, and/or syncope may be higher.
[L45678]
The carcinogenicity of plerixafor has not been evaluated, and the effect of plerixafor on human fertility is unknown. According to the results from an in vitro bacterial mutation assay, an in vitro chromosomal aberration test, and an in vivo bone marrow micronucleus test in rats after subcutaneous doses up to 25 mg/kg, plerixafor is not genotoxic.
[L45678]
In mice and rats, the LD₅₀ of plerixafor by intravenous injection is 5 mg/kg.

The LD₅₀ of plerixafor by subcutaneous injection is 16 mg/kg in mice and >50 mg/kg in rats/.
[L45688]

How it works

Mechanism of action

Plerixafor inhibits the C-X-C chemokine receptor type 4 (CXCR4) on CD34+ cells and reversibly blocks the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1α). SDF-1α and CXCR4 play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. In the marrow, stem cell CXCR4 can help anchor HSCs to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. By blocking the interaction between SDF-1α and CXCR4 with plerixafor, the mobilization of progenitor cells is triggered. Adding granulocyte-colony stimulating factor (G-CSF) to enhance CD34+ cell mobilization increases the yield of stem cells, an important determinant of graft adequacy.[A7113][A7114][L45678]

Pharmacodynamics

Plerixafor is a bicyclam derivative that antagonizes C-X-C chemokine receptor type 4 (CXCR4) by binding to three acidic residues in the ligand-binding pocket: Asp171, Asp262, and Glu288.[A7119][L45683] Blood levels of CD34+ cells peaked between 6 and 9 hours after the administration of 0.24 mg/kg plerixafor in healthy subjects. In combination with a granulocyte-colony stimulating factor (G-CSF), circulating CD34+ cells in the peripheral blood peaked between 10 and 14 hours. The use of plerixafor is not associated with QT/QTc prolongation at single doses up to 0.40 mg/kg.[L45678]

Serious hypersensitivity reactions, such as anaphylactic-type reactions, have occurred in patients receiving plerixafor. The use of plerixafor may also cause tumor cell mobilization in leukemia patients, splenic enlargement and rupture, embryo-fetal toxicity, and hematologic effects, such as leukocytosis and thrombocytopenia. When used in combination with G-CSF for hematopoietic stem cell mobilization‚ plerixafor may lead to the release of tumor cells from the marrow and their subsequent collection in the leukapheresis product.[L45678]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Plerixafor follows a two-compartment pharmacokinetic profile with first-order absorption and exhibits linear kinetics between 0.04 mg/kg and 0.24 mg/kg. The pharmacokinetic profile of plerixafor in healthy subjects was similar to the one observed in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) who received plerixafor in combination with granulocyte-colony stimulating factor (G-CSF). In addition, the clearance of plerixafor has a significant relationship with creatinine clearance (CL_CR).

The population pharmacokinetic analysis showed that, with increasing body weight, a mg/kg-based dosage leads to a higher plerixafor exposure (AUC_0-24h). However, NHL patients (<70 kg) given a fixed dose of 20 mg of plerixafor had an AUC_0-10h 1.43-fold higher than the one detected in patients given 0.24 mg/kg of plerixafor. Therefore, a body weight of 83 kg was selected as an appropriate cut-off point to transition patients from fixed to weight-based dosing.
[L45678]

Peak concentrations are reached in approximately 30-60 minutes (t_max) following subcutaneous injection.
[L45678][L45683]
In patients given 0.24 mg/kg of plerixafor subcutaneously after receiving 4-days of G-CSF pre-treatment, the C_max and AUC_0-24 were 887 ng/ml and 4337 ng·hr/ml, respectively.
[L45683]

Half-life

Plerixafor has a distribution half-life of 0.3 hours and a terminal population half-life of 5.3 hours in patients with normal renal function. In studies with healthy subjects and patients, the terminal half-life in plasma ranges between 3 and 5 hours.
[L45678]
In patients with non-Hodgkin lymphoma, the terminal half-life of plerixafor is 4.4 hours, and in patients with multiple myeloma, the terminal half-life is 5.6 hours.
[A7116]

Protein binding

The human plasma protein binding of plerixafor is up to 58%.
[L45678]

Volume of distribution

Plerixafor has an apparent volume of distribution of 0.3 L/kg.
[L45678]

Metabolism

Plerixafor is not metabolized by the liver and is not a metabolism-dependent inhibitor of major cytochrome P450 enzymes, including 1A2, 2C9, 2C19, 2D6 and 3A4. In addition, it does not induce cytochrome P450 1A2, 2B6, or 3A4 enzymes.
[L45678]
Plerixafor is metabolically stable, and in vivo studies in rats and dogs showed that the non-parent radiolabelled components in plasma and urine were Cu2+ complexes with plerixafor. This is consistent with the presence of two cyclam rings in plerixafor, which may act as potential chelating sites.
[L45713]

Route of elimination

Plerixafor is mainly eliminated through urine. In healthy volunteers with normal renal function given 0.24 mg/kg of plerixafor, approximately 70% of the parent drug is excreted in urine in the first 24 hours. An in vitro study with MDCKII and MDCKII-MDR1 cell models found that plerixafor is not a substrate or inhibitor of P-glycoprotein.
[L45678]

Clearance

Plerixafor has a total plasma clearance of 4.38 L/h, and a renal clearance of 3.15 L/h.
[A7116][A258423]

Drug targets(1)

Proteins and enzymes this drug interacts with in the body

C-X-C chemokine receptor type 4

CXCR4

antagonist

inhibitor

Specific functionactin binding

Cellular location

Cell membrane

General function & pharmacology

Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation .
PMID:10452968 PMID:18799424 PMID:24912431 PMID:28978524

Involved in the AKT signaling cascade .
PMID:24912431
Plays a role in regulation of cell migration, e.g. during wound healing .
PMID:28978524
Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels .
PMID:20228059
Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes .
PMID:11276205
Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development.

In the CNS, could mediate hippocampal-neuron survival (By similarity)

Scientific references(8)

Uy G.L., Rettig M.P., Cashen A.F.

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.

Expert Opinion Biological Therapeutics

2008 Nov8(11):1797-804. doi: 10.1517/14712598.8.11.1797

PMID: 18847313 DOI: 10.1517/14712598.8.11.1797

Fricker S.P.

A novel CXCR4 antagonist for hematopoietic stem cell mobilization.

Expert Opinion Investig Drugs

2008 Nov17(11):1749-60. doi: 10.1517/13543784.17.11.1749

PMID: 18922110 DOI: 10.1517/13543784.17.11.1749

DiPersio J.F., Stadtmauer E.A., Nademanee A., Micallef I.N., Stiff P.J., Kaufman J.L., Maziarz R.T., Hosing C., Fruehauf S., Horwitz M., Cooper D., Bridger G., Calandra G.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

Blood

2009 Jun 4113(23):5720-6. doi: 10.1182/blood-2008-08-174946. Epub 2009 Apr 10

PMID: 19363221 DOI: 10.1182/blood-2008-08-174946

Stewart D.A., Smith C., MacFarland R., Calandra G.

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Biological Blood Marrow Transplant

2009 Jan15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018

PMID: 19135941 DOI: 10.1016/j.bbmt.2008.10.018

Brave M., Farrell A., Ching Lin S., Ocheltree T., Pope Miksinski S., Lee S.L., Saber H., Fourie J., Tornoe C., Booth B., Yuan W., He K., Justice R., Pazdur R.

FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.

Oncology

201078(3-4):282-8. doi: 10.1159/000315736. Epub 2010 Jun 8

PMID: 20530974 DOI: 10.1159/000315736

Choi H.Y., Yong C.S., Yoo B.K.

Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.

Ann Pharmacother

2010 Jan44(1):117-26. doi: 10.1345/aph.1M380. Epub 2009 Dec 15

PMID: 20009003 DOI: 10.1345/aph.1M380

Keating G.M.

Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Drugs

2011 Aug 2071(12):1623-47. doi: 10.2165/11206040-000000000-00000

PMID: 21861545 DOI: 10.2165/11206040-000000000-00000

MacFarland R., Hard M.L., Scarborough R., Badel K., Calandra G.

A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.

Biological Blood Marrow Transplant

2010 Jan16(1):95-101. doi: 10.1016/j.bbmt.2009.09.003. Epub 2009 Sep 10

PMID: 19748593 DOI: 10.1016/j.bbmt.2009.09.003

ATC classification(1 code)

ATC L03AX16

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Plerixafor octahydrochloride(DBSALT002325)

Experimental properties(3)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(1)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Plerixafor

CAS number

110078-46-1

UNII (FDA)

S915P5499N

InChI Key (molecular fingerprint)

YIQPUIGJQJDJOS-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

21077

ChEBI

125354

PubChem Compound

65015

PubChem Substance

99443297

KEGG Drug

D08971

ChemSpider

58531

BindingDB

50035696

PharmGKB

PA165958410

PDB

VH6

IUPHAR

844

Guide to Pharmacology

844

Wikipedia

Plerixafor

ChEMBL

CHEMBL18442

ZINC

ZINC000022443609

RxCUI

733003

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2561

GenAtlas

CXCR4

GeneCards

CXCR4

GenBank Gene Database

L01639

GenBank Protein Database

189314

IUPHAR

71

Guide to Pharmacology

71

UniProtKB

P61073

UniProt Accession

CXCR4_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite:

DrugBank 6.02024Recommended citation
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
PMID: 37953279
DrugBank 5.02018
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
PMID: 29126136
DrugBank 4.02014
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
PMID: 24203711
DrugBank 3.02011
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
PMID: 21059682
DrugBank 2.02008
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
PMID: 18048412
DrugBank 1.02006
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 Mar 2026

Back to medicines